Business Wire

CLEO

20.5.2019 09:02:06 CEST | Business Wire | Press release

Share
Cleo to Showcase End-to-End Approach to Ecosystem Integration at Gartner AADI in London

Gartner’s Application Architecture, Development & Integration (AADI) Summit returns to London to provide strategies for solving the pervasive challenges of orchestrating workflows between external B2B and application ecosystems with internal business systems. Cleo , the global leader in ecosystem integration solutions, will be exhibiting in Booth S3 to demonstrate how successful organisations leverage its “outside-in” approach to create seamless end-to-end workflows and help optimize business processes.

The Gartner AADI 2019 event , taking place 20-21 May at Park Plaza Westminster, is designed to empower IT and business professionals in transforming their application architecture, agile development, and integration strategies. The event’s focus on application strategies and data processes in the era of the cloud highlights the need for better ways to execute application integration, an inescapable challenge in today’s business landscape.

According to the 2019 State of Ecosystem and Integration Application Report , integration is a constant battle for organisations, with 25% of companies struggling to integrate new applications with legacy systems. All told, unreliable partner and application integrations are costing companies approximately $500,000 every year. Cleo will showcase at the Gartner AADI summit how to solve these challenges using an innovative approach that integrates the dynamic ecosystem of people, partners, customers, systems, applications, and things and supports the critical data flows driving revenue.

About Cleo Integration Cloud

Today’s data exchange requirements often are dictated by the partners, suppliers, customers, vendors, and all their respective technologies comprising a modern business ecosystem, and it demands a change in how we view traditional integration patterns. Conference-goers visiting the Cleo booth will learn hands-on about the business benefits of technology embracing this fresh POV – integration that prioritises external customer and trading partner data processes and integrates them seamlessly into internal workflows – via the Cleo Integration Cloud platform.

Cleo’s flagship offering is a single, hybrid integration platform enabling organisations to connect, transform, integrate, orchestrate, and analyse end-to-end application, B2B, cloud, and data integrations for improved visibility across global business ecosystems. Cleo Integration Cloud facilitates the heavy lifting of integration while also providing dynamic dashboards to empower technical and business users to make better decisions, create stronger relationships with trading partners, and accelerate growth as data requirements evolve. The result is end-to-end transparency throughout internal networks and external business ecosystems, which enables organisations to maximise the value of their application investments.

Agenda Highlights

The opening keynote for this year’s Gartner AADI summit is titled, “Optimize, Integrate and Transform to Achieve Your Digital Future” and features Gartner’s Elizabeth Golluscio, managing vice president, Keith Guttridge, senior director analyst, and Mark O'Neill, VP analyst. The speakers will explore how organisations pursuing digital transformation must apply modern digital application and integration strategies to advance those initiatives.

The agenda also features a number of topics spanning cloud integration challenges, strategic application trends, modernising core systems, postmodern ERP integration, and how smart application integration delivers next-generation customer experiences. The nature of the 2019 agenda further emphasizes the value an ecosystem-driven approach can have in designing application integration processes that support innovation, align with business goals, and deliver competitive advantage.

“Organisations are at a tipping point in how they integrate all the ERPs, CRMs, e-commerce, and other business-critical applications they deploy almost daily,” said Cleo CMO Tushar Patel . “It’s individual departments and lines of business that are driving technology investment, rather than the traditional IT teams, and it requires a change in how they approach application integration. Today’s integration technology should give companies a path to optimising their core business processes while solving external B2B and internal application integration challenges simultaneously.”

Patel adds: “The companies treating application and B2B interactions as separate, disparate business processes are leaving value on the table and will get left behind.”

Come see Cleo at Booth S3 for a Cleo-themed cocktail – an “Ecosystem Integration Elixir” – and to learn how Cleo customers are achieving success every day with Cleo Integration Cloud. To learn more about Cleo, and how Cleo Integration Cloud can help your business, visit our website – www.cleo.com .

For more insights on what to expect at the event, read the blog titled, “Ecosystem Integration & Value Beyond the Gartner AADI London Agenda.”

About Gartner AADI 2019

The Gartner Application Architecture, Development & Integration Summit 2019 is designed for application leaders to learn about crafting leading-edge applications, architectures and strategies leveraging microservices, DevOps and artificial intelligence, and more. Attendees can gain intensive learning and actionable insight as they plan to drive growth through digital business transformation.

About Cleo

Cleo is an ecosystem integration software company focused on business outcomes, ensuring each customer’s potential is realized by delivering solutions that make it easy to discover and create value through the movement and integration of enterprise data. Cleo gives customers a strategic, “outside-in” visibility into the critical end-to-end business flows happening across their ecosystems of partners and customers, marketplaces, and internal cloud and on-premise applications. Our solutions empower teams to drive business agility, accelerate onboarding, facilitate modernisation of key business processes, and capture new revenue streams by reimagining and remastering their digital ecosystem through robust application, B2B, and data integration technologies. For more information, visit www.cleo.com or call +1.815.282.7695.

Contact:

Media Contacts Matt Torman Senior Manager, Marketing Communications Cleo +1.815.282.7610

Drew Smith Senior Account Manager 10Fold Communications (for Cleo) +1.415.800.5374

Link:

ClickThru

Social Media:

https://www.facebook.com/CleoCommunications

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye